Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Intracel Corporation



INTRACEL Corporation is a biopharmaceutical company developing and commercializing cancer vaccines and immunotherapeutic products for cancer and infectious diseases. The company has built a large portfolio of product candidates. Most advanced of which, OncoVAX® , is a vaccine for Stage II colon cancer patients and is currently being marketed and provided on a commercial basis in the Netherlands. Late-Stage product candidates include: KLH (Keyhole Limpet Hemocyanin) for advanced bladder cancer and OncoVAX® for Stage III colon cancer patients, which are both in Phase III development. INTRACEL has a number of fully human monoclonal antibodies in earlier stages of development to treat respiratory syncytial virus (RSV), major hospital infections and autoimmune disorders. The antibodies have emerged from a powerful discovery platform base that combines phage display technology with one of the world’s largest repositories of human antibody responses.



The company plans to commercialize these products through direct investments and corporate partnerships. As part of its business strategy, INTRACEL operates a revenue generating research reagent business.


Contact Details:
93 Monocacy Blvd., Unit A-8
Frederick
MD
21701
United States of America
Tel:(301) 668-8400
Fax:(301) 668-6317
Email:info@intracel.com
WWW:

www.intracel.com/




Loading...

Recent Publications by Intracel Corporation:

Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological Pharmacodynamics.
In the area of cancer treatment, immunotherapy with vaccines has suffered...
27th October, 2006
Intracel, Frederick, Hum Vaccin. 2006 Jul-Aug;2(4):185-91. Epub 2006 Jul 6.
Global harmonization of regulatory requirements for premarket approval of autologous cell therapies.
In the area of cancer treatment, immunotherapy with vaccines has suffered...
12th October, 2002
INTRACEL Corp., Rockville, Maryland, USA. Food Drug Law J. 2000;55(2):225-43.

Intracel Corporation Clinical Trials:

Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery

Intracel Corporation Patents:

US Patent No.Title
7488477 Neutralizing monoclonal antibodies to respiratory syncytial virus
5561045 Detection reagent, article, and immunoassay method
5547833 Radial flow assay, delivering member, test kit, and methods
4962047 Mixing and separating solid phase supports by pressure variation
4960693 System of reactants involving an apo-enzyme useful in immunological analysis and a method for carrying out immuoassays with this system

View more Intracel Corporation patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 577 times since April 2007, the link to the organisation's website has been followed 149 times

Recent Search Terms used to find this page: INTRACEL corporation | oncovax phage | intracel phage | Intracel phage display | Intracel phage | intracel | Intracel Corporation | Intracel Corporation | intracel immunotherapy | Intracel | .

Search for more companies in Frederick

Search for more companies in MD



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Intracel Corporation

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.